| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000019821 |
| Receipt No. | R000022830 |
| Scientific Title | Development of novel miniscrew. |
| Date of disclosure of the study information | 2015/11/30 |
| Last modified on | 2020/11/20 (Ver. 5) |
| Basic information | ||
| Public title | Development of novel miniscrew. | |
| Acronym | Development of novel miniscrew. | |
| Scientific Title | Development of novel miniscrew. | |
| Scientific Title:Acronym | Development of novel miniscrew. | |
| Region |
|
|
| Condition | ||
| Condition | Malocclusion | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Nowadays, orthodontic miniscrew implants were newly developed and have been well accepted in all over the world because this provides absolute anchorage without patient's compliance. Miniscrew can provide stable anchorage for various type of tooth movements, including intrusion, retraction, and protraction, resulting in achievements of ideal occlusion and facial balance. However, the clinical use of miniscrew implants especially for long time, accompanies some risks and complications. Screw failure is one of the most undesirable problems, and a recent review found an overall failure rate of 23.2%. This rate is significantly higher than the failure rate of dental implants for prosthetic restorations. Truly, in clinical orthodontics, several cases showed one or more experiences of screw failure, which affects treatment outcome and duration. Rarely, failed miniscrew could be a risk factor for pulmonary aspiration. Therefore, increasing the success rate of miniscrew implants in clinical orthodontics is an urgent issue. In this study, the aim is to develop a novel miniscrew with higher success rate, which contributes to a safe and effective orthodontic treatment. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Stability of miniscrew implants (at 1-3 months after implantation) |
| Key secondary outcomes | The tightening torque and loosening torque of miniscrew implants (after implantation immediately) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Novel developed miniscrew (NDM) group: patients with implantation of NDM between the date of approval and March 2020.
Duration of interventional study: During multi-bracket treatment (approximately 2-3 years) Number of intervention: Implant the required number of NDM needed to treat. However, the upper limit per patient to the six. |
|
| Interventions/Control_2 | Conventional miniscrew (CM) group: patients treated with CM between the date of April 2008 and September 2015. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients will have been diagnosed with the application of miniscrew implants between the date of approval and March 2020. | |||
| Key exclusion criteria | ・Unmanageable severe systemic disease
・Unmanageable bleeding disorder, Uncooperative patients without motivation ・Drugs, alcohol, nicotine addiction patients, and dysfunction of treatment resistance for long time ・Xerostomia ・Opportunistic immunodeficiency and leukocyte dysfunction ・Diseases requiring a regular steroid ・Unmanageable endocrine disease ・Hypersensitivity to titanium/ titanium alloy ・Abnormal wound healing function ・Administered bisphosphonates ・Not in good general condition ・The implanted area has some problems such as inflammation, tumors, cysts, lesions, and trauma |
|||
| Target sample size | 400 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Tokushima University Graduate School | ||||||
| Division name | Department of Orthodontics and Dentofacial Orthopedics, Institute of Biomedical Sciences | ||||||
| Zip code | 7708504 | ||||||
| Address | 3-18-15, Kuramotocho, Tokushima, Tokushima, Japan | ||||||
| TEL | 088-633-7357 | ||||||
| etanaka@tokushima-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Tokushima University Graduate School | ||||||
| Division name | Department of Orthodontics and Dentofacial Orthopedics, Institute of Biomedical Sciences | ||||||
| Zip code | 7708504 | ||||||
| Address | 3-18-15, Kuramotocho, Tokushima, Tokushima, Japan | ||||||
| TEL | 088-633-7357 | ||||||
| Homepage URL | |||||||
| nabe@tokushima-u.ac.jp | |||||||
| Sponsor | |
| Institute | Department of Orthodontics and Dentofacial Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School |
| Institute | |
| Department | |
| Funding Source | |
| Organization | BIODENT CORPORATION |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | IRB, Tokushima University Hospital |
| Address | Kuramoto-cho 2-50-1, Tokushima, Tokushima |
| Tel | 0886339294 |
| awachiken@tokushima-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000022830 |